Home › Trials › NCT06952530

Orforglipron for treating high blood pressure in adults with overweight or obesity

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)

Phase 3 Interventional Eli Lilly and Company · NCT06952530

This trial will test whether orforglipron can lower blood pressure in adults who have hypertension and are overweight or have obesity.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment487 (estimated)
Ages18 Years and up
SexAll
SponsorEli Lilly and Company Industry-sponsored
Locations99 sites (Phoenix, Arizona and 98 other locations)
Trial IDNCT06952530 on ClinicalTrials.gov

What this trial studies

This is a phase 3, randomized, placebo-controlled arm conducted under the GZPL master protocol to test orforglipron in people with hypertension and excess weight. Participants are randomized to receive orforglipron or placebo and are followed for blood pressure outcomes and safety measures according to the master protocol. The trial is conducted at multiple U.S. clinical research sites and uses standardized blood pressure measurements and safety monitoring. Detailed eligibility criteria and study procedures follow the GZPL master protocol.

Who should consider this trial

Good fit: Adults with diagnosed hypertension who are overweight or have obesity and who meet the GZPL master protocol screening criteria are the intended participants.

Not a fit: People who do not have overweight or obesity, who have forms of secondary hypertension, or who are excluded by the GZPL master protocol (for example due to specific comorbidities or contraindications) may not receive benefit from participating.

Why it matters

Potential benefit: If successful, it could offer a new medication option that lowers blood pressure and may provide weight-related metabolic benefits for people with hypertension who are overweight or have obesity.

How similar studies have performed: Other trials of orforglipron and related GLP-1 receptor agonists have shown weight loss and metabolic improvements, but specific, definitive evidence for blood pressure lowering with orforglipron is limited and is the focus of this trial.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* refer to the GZPL master protocol study for screening eligibility.

Exclusion Criteria:

* refer to the GZPL master protocol study for screening eligibility.

Where this trial is running

Phoenix, Arizona and 98 other locations

+49 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Hypertension
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.